09:43 AM EDT, 07/16/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Wednesday that translational data for its intravenously delivered immunotherapeutic agent, pelareorep, showed effectiveness of the therapy across multiple tumor types.

The data confirmed viral replication, interferon signaling, and a surge in tumor-infiltrating lymphocytes after pelareorep treatment, the company said.

Oncolytics Biotech ( ONCY ) added that the data reinforces pelareorep's ability to convert immunologically "cold" tumors into "hot" phenotypes, paving the way for registration-enabling trials.

Shares were up 2.7% in recent early trading.

Price: 1.16, Change: +0.03, Percent Change: +2.65